Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Asheville, NC
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Asheville, NC
Click here to add this to my saved trials
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Charlotte, NC
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Hershey, PA
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Hershey, PA
Click here to add this to my saved trials
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Columbia, SC
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Columbia, SC
Click here to add this to my saved trials
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Richardson, TX
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Richardson, TX
Click here to add this to my saved trials
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
San Antonio, TX
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Sugar Land, TX
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Sugar Land, TX
Click here to add this to my saved trials
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
Status: Enrolling
Updated:  10/7/2015
Clinical Research Facility
mi
from
Ogden, UT
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
Status: Enrolling
Updated: 10/7/2015
Clinical Research Facility
mi
from
Ogden, UT
Click here to add this to my saved trials
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
Status: Enrolling
Updated:  10/7/2015
Research Site
mi
from
Kurralta Park,
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
Status: Enrolling
Updated: 10/7/2015
Research Site
mi
from
Kurralta Park,
Click here to add this to my saved trials
My Lifestyle Intervention of Food and Exercise
Preventing Breast Cancer Recurrence Through a Tailored Lifestyle Intervention.
Status: Enrolling
Updated:  10/8/2015
University of Florida
mi
from
Gainesville, FL
My Lifestyle Intervention of Food and Exercise
Preventing Breast Cancer Recurrence Through a Tailored Lifestyle Intervention.
Status: Enrolling
Updated: 10/8/2015
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
My Lifestyle Intervention of Food and Exercise
Preventing Breast Cancer Recurrence Through a Tailored Lifestyle Intervention.
Status: Enrolling
Updated:  10/8/2015
University of North Florida
mi
from
Jacksonville, FL
My Lifestyle Intervention of Food and Exercise
Preventing Breast Cancer Recurrence Through a Tailored Lifestyle Intervention.
Status: Enrolling
Updated: 10/8/2015
University of North Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer
A Biobehavioral Intervention for Patients With Gynecologic or Breast Cancer Recurrence
Status: Enrolling
Updated:  10/8/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer
A Biobehavioral Intervention for Patients With Gynecologic or Breast Cancer Recurrence
Status: Enrolling
Updated: 10/8/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Identifying Circulating Breast Cancer Cells in Women With Metastatic Breast Cancer
A Feasibility Study of a Novel Technique to Identify Circulating Breast Cancer Cells in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  10/9/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Identifying Circulating Breast Cancer Cells in Women With Metastatic Breast Cancer
A Feasibility Study of a Novel Technique to Identify Circulating Breast Cancer Cells in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 10/9/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Assessment of Ability of Breath Hold for Left-sided Breast Cancer Radiation Therapy to Reduce Side Effects to Heart
Prospective Pilot Study of Assessment of Breath Hold as a Means to Mitigate the Risk of Radiation-associated Reductions in Regional Cardiac Perfusion in Patients With Left-sided Breast Cancer
Status: Enrolling
Updated:  10/9/2015
University of North Carolina at Chapel Hill, Department of Radiation Oncology
mi
from
Chapel Hill, NC
Assessment of Ability of Breath Hold for Left-sided Breast Cancer Radiation Therapy to Reduce Side Effects to Heart
Prospective Pilot Study of Assessment of Breath Hold as a Means to Mitigate the Risk of Radiation-associated Reductions in Regional Cardiac Perfusion in Patients With Left-sided Breast Cancer
Status: Enrolling
Updated: 10/9/2015
University of North Carolina at Chapel Hill, Department of Radiation Oncology
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Status: Enrolling
Updated:  10/9/2015
UCLA Medical Center
mi
from
Los Angeles, CA
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Status: Enrolling
Updated: 10/9/2015
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Status: Enrolling
Updated:  10/9/2015
Wilshire Oncology Medical Group, Inc.
mi
from
Pomona, CA
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Status: Enrolling
Updated: 10/9/2015
Wilshire Oncology Medical Group, Inc.
mi
from
Pomona, CA
Click here to add this to my saved trials
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Status: Enrolling
Updated:  10/9/2015
Cancer Institute Of Florida
mi
from
Orlando, FL
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Status: Enrolling
Updated: 10/9/2015
Cancer Institute Of Florida
mi
from
Orlando, FL
Click here to add this to my saved trials
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Status: Enrolling
Updated:  10/9/2015
Northwest Georgia Oncology Centers, PC
mi
from
Marietta, GA
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Status: Enrolling
Updated: 10/9/2015
Northwest Georgia Oncology Centers, PC
mi
from
Marietta, GA
Click here to add this to my saved trials
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Status: Enrolling
Updated:  10/9/2015
South Texas Oncology and Hematology
mi
from
San Antonio, TX
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Status: Enrolling
Updated: 10/9/2015
South Texas Oncology and Hematology
mi
from
San Antonio, TX
Click here to add this to my saved trials
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Status: Enrolling
Updated:  10/9/2015
Cross Cancer Institute
mi
from
Edmonton,
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Status: Enrolling
Updated: 10/9/2015
Cross Cancer Institute
mi
from
Edmonton,
Click here to add this to my saved trials
Capecitabine in Treating Patients With Metastatic Breast Cancer
Phase II Study of Fixed-Dose Capecitabine in Metastatic Breast Cancer
Status: Enrolling
Updated:  10/9/2015
DeCesaris Cancer Institute at Anne Arundel Medical Center
mi
from
Annapolis, MD
Capecitabine in Treating Patients With Metastatic Breast Cancer
Phase II Study of Fixed-Dose Capecitabine in Metastatic Breast Cancer
Status: Enrolling
Updated: 10/9/2015
DeCesaris Cancer Institute at Anne Arundel Medical Center
mi
from
Annapolis, MD
Click here to add this to my saved trials
Capecitabine in Treating Patients With Metastatic Breast Cancer
Phase II Study of Fixed-Dose Capecitabine in Metastatic Breast Cancer
Status: Enrolling
Updated:  10/9/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Capecitabine in Treating Patients With Metastatic Breast Cancer
Phase II Study of Fixed-Dose Capecitabine in Metastatic Breast Cancer
Status: Enrolling
Updated: 10/9/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Capecitabine in Treating Patients With Metastatic Breast Cancer
Phase II Study of Fixed-Dose Capecitabine in Metastatic Breast Cancer
Status: Enrolling
Updated:  10/9/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Capecitabine in Treating Patients With Metastatic Breast Cancer
Phase II Study of Fixed-Dose Capecitabine in Metastatic Breast Cancer
Status: Enrolling
Updated: 10/9/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By Surgery
Effects of Surgery, Radiation Therapy, Chemotherapy, and Endocrine Therapy on High-Sensitivity C-Reactive Protein in Women With Operable Breast Cancer
Status: Enrolling
Updated:  10/9/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By Surgery
Effects of Surgery, Radiation Therapy, Chemotherapy, and Endocrine Therapy on High-Sensitivity C-Reactive Protein in Women With Operable Breast Cancer
Status: Enrolling
Updated: 10/9/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Collecting Information From Patients Enrolled in the Breast Specialized Program of Research Excellence
The Breast Cancer Specialized Program of Research Excellence (SPORE): Core A-Administrative/Biostatistics Core
Status: Enrolling
Updated:  10/11/2015
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Collecting Information From Patients Enrolled in the Breast Specialized Program of Research Excellence
The Breast Cancer Specialized Program of Research Excellence (SPORE): Core A-Administrative/Biostatistics Core
Status: Enrolling
Updated: 10/11/2015
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma
Phase I Evaluation of Interferon-alpha-1b in Solid Tumors, Lymphoma or Myeloma
Status: Enrolling
Updated:  10/11/2015
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma
Phase I Evaluation of Interferon-alpha-1b in Solid Tumors, Lymphoma or Myeloma
Status: Enrolling
Updated: 10/11/2015
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin
Phase 1/2 Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin
Status: Enrolling
Updated:  10/12/2015
Premiere Oncology of Arizona
mi
from
Scottsdale, AZ
Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin
Phase 1/2 Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin
Status: Enrolling
Updated: 10/12/2015
Premiere Oncology of Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin
Phase 1/2 Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin
Status: Enrolling
Updated:  10/12/2015
Arizona Cancer Center
mi
from
Tucson, AZ
Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin
Phase 1/2 Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin
Status: Enrolling
Updated: 10/12/2015
Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin
Phase 1/2 Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin
Status: Enrolling
Updated:  10/12/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin
Phase 1/2 Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin
Status: Enrolling
Updated: 10/12/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
University of Arizona / Arizona Cancer Center AZ Onc Assoc
mi
from
Tucson, AZ
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
University of Arizona / Arizona Cancer Center AZ Onc Assoc
mi
from
Tucson, AZ
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
University of Arizona / Arizona Cancer Center Deptof Uof A/Arizona Cancer(3)
mi
from
Tucson, AZ
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
University of Arizona / Arizona Cancer Center Deptof Uof A/Arizona Cancer(3)
mi
from
Tucson, AZ
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
University of California San Diego La Jolla - UCSD Moores Cancer
mi
from
La Jolla, CA
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
University of California San Diego La Jolla - UCSD Moores Cancer
mi
from
La Jolla, CA
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Rocky Mountain Cancer Centers RMCC
mi
from
Greenwood Village, CO
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Rocky Mountain Cancer Centers RMCC
mi
from
Greenwood Village, CO
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Georgetown University/Lombardi Cancer Center Dept.of Lombardi CancerCtr (3)
mi
from
Washington,
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Georgetown University/Lombardi Cancer Center Dept.of Lombardi CancerCtr (3)
mi
from
Washington,
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Comprehensive Cancer Center - Boca Raton Deerfield Beach
mi
from
Boca Raton, FL
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Comprehensive Cancer Center - Boca Raton Deerfield Beach
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Comprehensive Cancer Center - Boca Raton Dept.of BocaRatonCompCanCtr
mi
from
Boca Raton, FL
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Comprehensive Cancer Center - Boca Raton Dept.of BocaRatonCompCanCtr
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Florida Cancer Specialists DeptofFloridaCancerSpecialists
mi
from
Fort Myers, FL
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Florida Cancer Specialists DeptofFloridaCancerSpecialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Memorial Hospital Memorial Cancer Institute
mi
from
Hollywood, FL
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Memorial Hospital Memorial Cancer Institute
mi
from
Hollywood, FL
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
MD Anderson Cancer Center - Orlando Dept.ofMDACC-Orlando(2)
mi
from
Orlando, FL
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
MD Anderson Cancer Center - Orlando Dept.ofMDACC-Orlando(2)
mi
from
Orlando, FL
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Emory University School of Medicine/Winship Cancer Institute Dept.of WinshipCancerInst. (2)
mi
from
Atlanta, GA
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Emory University School of Medicine/Winship Cancer Institute Dept.of WinshipCancerInst. (2)
mi
from
Atlanta, GA
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
North Shore University Health System NSU
mi
from
Evanston, IL
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
North Shore University Health System NSU
mi
from
Evanston, IL
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Kansas City Cancer Center KCCC- South (2)
mi
from
Overland Park, KA
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Kansas City Cancer Center KCCC- South (2)
mi
from
Overland Park, KA
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Maryland Oncology Hematology
mi
from
Owning Mills, MD
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Maryland Oncology Hematology
mi
from
Owning Mills, MD
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Park Nicollet Institute Dept. of Park Nicollet
mi
from
St. Louis Park, MN
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Park Nicollet Institute Dept. of Park Nicollet
mi
from
St. Louis Park, MN
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
St. Louis University Cancer Center SLU Cancer Center
mi
from
St. Louis, MO
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
St. Louis University Cancer Center SLU Cancer Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
University of Nebraska Medical Center Unv Nebraska Med Ctr (2)
mi
from
Omaha, NE
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
University of Nebraska Medical Center Unv Nebraska Med Ctr (2)
mi
from
Omaha, NE
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Comprehensive Cancer Centers of Nevada CCC of Nevada Henderson (4)
mi
from
Las Vegas, NV
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Comprehensive Cancer Centers of Nevada CCC of Nevada Henderson (4)
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Nevada Cancer Institute Dept. of Nevada Cancer (3)
mi
from
Las Vegas, NV
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Nevada Cancer Institute Dept. of Nevada Cancer (3)
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated:  10/13/2015
Overlook Hospital - Carol G Simon Cancer Center Carol G Simon
mi
from
Summit, NJ
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.
Status: Enrolling
Updated: 10/13/2015
Overlook Hospital - Carol G Simon Cancer Center Carol G Simon
mi
from
Summit, NJ
Click here to add this to my saved trials